Valvoline Global Operations, a worldwide leader in automotive and industrial solutions creating future-ready products and best-in-class solutions for partners around the globe, is investing in building brighter futures for children with blood cancer.

Valvoline Global announced a $1-million commitment to The Leukemia & Lymphoma Society (LLS), over the next five years. The significant multi-year investment will be dedicated to the organization’s global Dare to Dream Project, which aims to transform treatment and care for pediatric blood cancer patients worldwide.

Inspire and enable

“At Valvoline Global, our purpose is to inspire and enable what—and who—move the world forward. That means teaming up with organizations like LLS to drive important causes forward and to create new solutions for a better tomorrow,” said Jamal Muashsher, President and CEO, Valvoline Global. “Cancer does not discriminate. It affects us all, in every corner of the world. With Valvoline Global’s presence in over 140 countries, the Dare to Dream Project is especially important to us as it strives to impact lives worldwide. We are honoured to join LLS in this essential global effort.”

Only five percent of cancer drugs have been approved for first-time use in children, while 80 percent of childhood cancer survivors develop chronic health issues from their treatment. Through Dare to Dream, LLS is responding to the urgent need for safer pediatric cancer treatments and better access to free support and resources for patients and their families.

For Ashley Havera, mother of 11-year old Maddie, who was diagnosed at age two with acute myeloid leukemia, the cause is personal. “We’re grateful to LLS for the work they are doing to support families like mine and childhood cancer patients,” she said. “When your child is diagnosed with cancer, it can be isolating. LLS was there throughout our journey, connecting us to resources and information we never would have discovered on our own, including treatment options. I am thrilled to see their work expanding further through the Dare to Dream Project to give more kids a greater chance to live fuller, healthier lives beyond cancer.”

LLS is leading international collaboration

Through Dare to Dream, LLS is leading international collaboration, convening some of the best minds in cancer research and treatment to fund the first-ever pediatric AML Data Commons, a platform that ensures consistency in global data reporting and launch the first-ever global pediatric acute leukemia Master Clinical Trial, LLS PedAL. Currently, there are 175 sites open across North America, Australia and New Zealand and 74 sites open in 17 countries for the therapeutic sub-study—bringing the dream of safer, more effective pediatric acute leukemia treatments closer to home for more people.

“We are grateful to Valvoline Global for their commitment to transforming treatment and care for kids with blood cancer,” said E. Anders Kolb, MD, President and Chief Executive Officer at LLS. “Through their generous support of Dare to Dream, LLS will be able to reach and support many more of the children and families who need us.”

To learn more about LLS’s Dare to Dream Project, please visit: https://www.lls.org/dare-to-dream.